Merck & Co. Inc. / Taiho Pharmaceutical / Astex Pharmaceuticals

KRAS-Mutant Solid Tumors (Pan-RAS / KRAS Inhibitor Discovery)

600K US cases/yr · $2.5B Projected global KRAS inhibitor market 2030 · ~$50M / ~$2.5B Upfront / total deal value (incl. milestones + royalties)

Disease Overview

KRAS is the most frequently mutated oncogene in human cancer, present in approximately 25% of all solid tumors including ~95% of pancreatic ductal adenocarcinoma (~64,000 U.S. cases/year), ~40% of colorectal cancer (~150,000 U.S. cases/year), and ~30% of non-small-cell lung cancer (~236,000 U.S. cases/year, with KRAS G12C the dominant subtype at ~13%). KRAS-mutant tumors carry historically poor prognoses and were considered undruggable for four decades after the gene's 1982 discovery, until Shokat lab's 2013 covalent G12C-binding strategy enabled the first clinical KRAS inhibitors. The U.S. KRAS-targeted oncology market opened with Lumakras (sotorasib, Amgen, FDA accelerated approval May 2021) and Krazati (adagrasib, Mirati/Bristol Myers, Dec 2022) for KRAS G12C NSCLC. Beyond G12C, the larger KRAS mutation universe (G12D, G12V, G13D, Q61H, others) remains largely unaddressed. The Merck-Taiho-Astex collaboration was structured as a discovery-stage research alliance targeting KRAS plus several additional small-molecule oncology targets, leveraging Astex's fragment-based drug discovery (FBDD) platform.

Competitive Landscape

The KRAS-targeted oncology landscape is dominated by KRAS G12C covalent inhibitors. Lumakras (sotorasib, Amgen) was first-in-class FDA-approved May 2021 for KRAS G12C NSCLC; the confirmatory Phase 3 CodeBreaK 200 missed OS, leading to FDA Adcom controversy. Krazati (adagrasib, Mirati Therapeutics, acquired by Bristol Myers Squibb Oct 2023) won FDA approval Dec 2022. Beyond G12C, KRAS G12D inhibitors include MRTX1133 (Mirati/BMS, preclinical/early Phase 1) and HRS-4642 (Hengrui). Pan-KRAS and pan-RAS inhibitors include RMC-6236 (RAS multi-on, Revolution Medicines, Phase 1/2), divarasib/GDC-6036 (Roche, KRAS G12C Phase 2), and JDQ443/opnurasib (Novartis, KRAS G12C Phase 2). SHP2 inhibitors that block upstream RAS-pathway signaling include RMC-4630 (Revolution/Sanofi), TNO155 (Novartis), and JAB-3068 (Jacobio). Astex's FBDD platform partnered with Merck targeted multiple oncology mechanisms beyond KRAS — Merck did not disclose individual targets but the collaboration was positioned as a multi-mechanism discovery alliance.